» Articles » PMID: 31021245

Applications of CRISPR-Cas in Bioengineering, Biotechnology, and Translational Research

Overview
Journal CRISPR J
Specialty Molecular Biology
Date 2019 Apr 26
PMID 31021245
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

CRISPR technology is rapidly evolving, and the scope of CRISPR applications is constantly expanding. CRISPR was originally employed for genome editing. Its application was then extended to epigenome editing, karyotype engineering, chromatin imaging, transcriptome, and metabolic pathway engineering. Now, CRISPR technology is being harnessed for genetic circuits engineering, cell signaling sensing, cellular events recording, lineage information reconstruction, gene drive, DNA genotyping, miRNA quantification, cloning, site-directed mutagenesis, genomic diversification, and proteomic analysis . It has also been implemented in the translational research of human diseases such as cancer immunotherapy, antiviral therapy, bacteriophage therapy, cancer diagnosis, pathogen screening, microbiota remodeling, stem-cell reprogramming, immunogenomic engineering, vaccine development, and antibody production. This review aims to summarize the key concepts of these CRISPR applications in order to capture the current state of play in this fast-moving field. The key mechanisms, strategies, and design principles for each technological advance are also highlighted.

Citing Articles

Efficient repair of human genetic defect by CRISPR/Cas9-mediated interlocus gene conversion.

Yang F, Wang Y, Wang Q, Pang J, Liu G, Yang Y Life Med. 2025; 2(5):lnad042.

PMID: 39872888 PMC: 11749481. DOI: 10.1093/lifemedi/lnad042.


With a pinch of salt: metagenomic insights into Namib Desert salt pan microbial mats and halites reveal functionally adapted and competitive communities.

Martinez-Alvarez L, Ramond J, Vikram S, Leon-Sobrino C, Maggs-Kolling G, Cowan D Appl Environ Microbiol. 2023; 89(12):e0062923.

PMID: 37971255 PMC: 10734447. DOI: 10.1128/aem.00629-23.


Combined approaches for increasing fetal hemoglobin (HbF) and production of adult hemoglobin (HbA) in erythroid cells from β-thalassemia patients: treatment with HbF inducers and CRISPR-Cas9 based genome editing.

Finotti A, Gambari R Front Genome Ed. 2023; 5:1204536.

PMID: 37529398 PMC: 10387548. DOI: 10.3389/fgeed.2023.1204536.


Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β39-Globin Gene Editing and Induction of Fetal Hemoglobin.

Cosenza L, Zuccato C, Zurlo M, Gambari R, Finotti A Genes (Basel). 2022; 13(10).

PMID: 36292612 PMC: 9601852. DOI: 10.3390/genes13101727.


PAM-flexible dual base editor-mediated random mutagenesis and self-activation strategies to improve CRISPRa potency.

Lau C, Huang S, Lam R, Tin C Mol Ther Methods Clin Dev. 2022; 26:26-37.

PMID: 35755943 PMC: 9198377. DOI: 10.1016/j.omtm.2022.05.005.